Cargando…
Commentary: Reconsidering Pharmaceutical Research and Development Investments
Following Lee and colleagues' (2023) article explaining how Canadians are being shortchanged by drug companies when it comes to investments in research and development (R&D), this rejoinder adds context and appends two other very problematic elements in the debate between wishful narratives...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Longwoods Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019513/ https://www.ncbi.nlm.nih.gov/pubmed/36917451 http://dx.doi.org/10.12927/hcpol.2023.27037 |